An interventional study of Essilor® Stellest® spectacle lenses in Myopia, sponsored by Essilor International. Active, not recruiting at 3 sites in 3 countries. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Essilor International · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Myopia by EssilorLuxottica — 14 open to participants now, 19 under way, none of them phase 3. Myopia · EssilorLuxottica.
Among the 28 studies in Myopia by EssilorLuxottica, this one is the 4th largest by planned enrollment, is one of 2 that started in 2024, is one of 28 with no phase, reaches primary completion later than 9 of the 18 other live ones, and was the 8th registered.
1,160 studies on the registry are indexed under Myopia; 226 are open to participants now.
Browse Myopia studies →14 of the 28 studies in Myopia by EssilorLuxottica are open now, in 5 countries. Recruiting first, the newest first:
Essilor International · Sites in Singapore
Ages 6–13
Essilor International · Sites in France
Ages 12–17 · Healthy volunteers
Essilor International · Sites in France
Ages 6–14
Essilor International · Sites in France
Ages 6–12 · Healthy volunteers
Essilor International · Sites in China
Ages 6–12
By country, each count listing its studies:
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 150 is above the median of 79 across 924 interventional studies indexed under Myopia.
Median enrollment 52 across the 28 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Essilor International, one of the names counted as EssilorLuxottica. Under that name alone:
Essilor International is the lead sponsor of 38 studies on the registry; 20 are open to participants now.
6 of the studies in Myopia by EssilorLuxottica that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440134Essilor InternationalVisual and Postural Behavior in Myopic and Non-Myopic Teenagers | 2027-05 |
| NCT06263946Essilor InternationalEssilor® Stellest® Lenses Multicentre European Study (SLOMES) | 2027-05-04 |
| NCT07297810Essilor InternationalDevelopment of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People | 2027-06 |
| NCT06850168Essilor InternationalClinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression | 2027-10 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 28 studies in Myopia by EssilorLuxottica, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this post-market clinical follow up Study is to demonstrate the efficacy, safety, acceptability, and quality of life implications of Essilor® Stellest® spectacle lenses in slowing myopia progression in European children and adolescents. Participants will receive Essilor® Stellest® at inclusion visit and will be asked for a full time wear (>12 hours daily) for 24 months. The primary endpoints are the change in axial length and cycloplegic autorefraction from baseline to 24 months compared to expected change based on axial length and refraction centile positions at baseline.
The trial design is a multicentre, European, prospective, interventional study with single group assignment. The investigational medical device Essilor® Stellest® is a CE marked, myopia control spectacle lens. The trial period for all participants is 24 months. The recruiting period is 6 to 9 months depending on countries / sites for a total of 150 participants (50 in Ireland, 75 in France and 25 in The Netherlands).
The secondary objectives are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Myopia as determined by cycloplegic autorefraction as follows:
Exclusion Criteria:
- Eye diseases/conditions:
patients will be asked to wear Essilor® Stellest® spectacle lenses for a full time wear (\>12 hours daily) for 24 months
Device: Essilor® Stellest® spectacle lenses
patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.
Change in cycloplegic axial length
in mm (millimeter) compared to expected change based on axial length at baseline (in each eye).
Time frame: from baseline to 24 months
Change in cycloplegic autorefraction
in D (Diopter) compared to expected change based on refraction centile positions at baseline (in each eye).
Time frame: from baseline to 24 months
Change in refraction progression centile
compared to expected change based on refraction centile positions at baseline (in each eye).
Time frame: from 12 months to 24 months visits.
Change in cycloplegic axial length
in mm (millimeter) compared to expected change based on axial length at baseline (in each eye).
Time frame: from baseline to 12 months and 24 months
Change in cycloplegic autorefraction
compared to expected change based on refraction centile positions at baseline (in each eye).
Time frame: from baseline to 12 months and 24 months
Change in refraction
in D (Diopter) compared to that observed in control group participants of MOSAIC Study (myopia control trial conducted in Ireland from 2019 to 2023) (in each eye)
Time frame: during the first and second year of the Myopia Outcome Study of Atropine In Children (MOSAIC) study
Change in axial length
in mm (millimeter) compared to that observed in control group participants of the MOSAIC study (in each eye)
Time frame: during the first and second year (separate comparisons for each year) of the MOSAIC study.
Change in choroidal thickness
in μm (micrometre) compared to that observed in control group participants of the MOSAIC study (in each eye)
Time frame: during the first and second year (separate comparisons for each year) of the MOSAIC study.
Change in refraction
in D (Diopter) compared to children treated with 0.01% atropine in group participants of the MOSAIC study (in each eye)
Time frame: during the first and second year (separate comparisons for each year) of the MOSAIC study.
Change in axial length vs atropine
in mm (millimeter) compared to children treated with 0.01% atropine in group participants of the MOSAIC study (in each eye)
Time frame: during the first and second year (separate comparisons for each year) of the MOSAIC study.
Change in choroidal thickness
in μm (micrometre) compared to children treated with 0.01% atropine in group participants of the MOSAIC study (in each eye)
Time frame: during the first and second year (separate comparisons for each year) of the MOSAIC study
Change in Paediatric Refractive Error Profile (PREP-2) score
Change in Paediatric Refractive Error Profile (PREP-2) score
Time frame: from baseline (pre- Essilor® Stellest®) to 12 and 24 months (post- Essilor® Stellest®)
Plan to share: No
Started Mar 2024 (actual). Primary completion is estimated for May 2027, 37 months after the start.
Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 37 months is above that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.